ClinicalTrials.gg
CompletedNCT06192108ACHIEVE-2Updated Oct 16, 2026Results posted

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

A Phase 3 interventional study of Orforglipron and Dapagliflozin in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 74 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
962
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
5th of 15
962 · median 546
Started
2024
the only one that year
Phase 3
11 of 15
2 open now
Registered
10th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 11 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
  • Have ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
  • Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization.
  • Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
  • Have a (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D)
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have an estimated (eGFR) \<45 milliliter per minute (mL/min)/1.73 square meter (m2)
  • Have acute or chronic hepatitis
  • Have had chronic or acute pancreatitis any time.
  • Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
962 participants (actual)

Study arms

  • Experimental
    Orforglipron 3 mg

    Participants received orforglipron, administered orally once daily (QD), starting at a dose of 1 milligram (mg) and escalated at week 4 to a dose of 3 mg, which was then maintained up to week 40.

    Drug: Orforglipron

  • Experimental
    Orforglipron 12 mg

    Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) until reaching a dose of 12 mg at week 12, which was then maintained up to week 40.

    Drug: Orforglipron

  • Experimental
    Orforglipron 36 mg

    Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg at week 12, and 24 mg at week 16) until reaching a dose of 36 mg at week 20, which was then maintained up to week 40.

    Drug: Orforglipron

  • Active comparator
    Dapagliflozin 10 mg

    Participants received dapagliflozin, administered orally QD, at a fixed dose of 10 mg starting at randomization, which was maintained up to week 40.

    Drug: Dapagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c [Noninferiority Analysis]

    * Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE were calculated using a mixed-model repeated measures (MMRM) analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<= \[less than or equal to\] 8.0% ,\> \[greater than\] 8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Change From Baseline in HbA1c [Superiority Analysis]

    * HbA1c is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  2. Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

    Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analyzed using a logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

    Time frame: Week 40

  3. Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)

    Percentage of participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

    Time frame: Week 40

  4. Percent Change From Baseline in Body Weight

    Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  5. Change From Baseline in Body Weight

    Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  6. Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol

    Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  7. Percent Change From Baseline in Triglycerides

    Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  8. Change From Baseline in Systolic Blood Pressure (SBP)

    Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  9. Change From Baseline in Fasting Serum Glucose (FSG)

    Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  10. Percentage of Participants With ≥ 5% Body Weight Reduction

    Percentage of participants with greater than or equal to (≥) 5% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

    Time frame: Week 40

  11. Percentage of Participants With ≥ 10% Body Weight Reduction

    Percentage of participants with ≥ 10% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

    Time frame: Week 40

  12. Percentage of Participants With ≥ 15% Body Weight Reduction

    Percentage of participants with ≥ 15% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

    Time frame: Week 40

  13. Change From Baseline in Diastolic Blood Pressure (DBP)

    Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  14. Percent Change From Baseline in Total Cholesterol

    Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  15. Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

    The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 40

  16. Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction

    The DTSQc assesses relative change in participant satisfaction with diabetes treatment compared to previous treatment. The questionnaire consists of 8 items, of which 6 items were used to calculate the Total Score of Treatment Satisfaction, covering the following:1. satisfaction with current treatment; 2. convenience of treatment; 3. flexibility; 4. satisfaction with understanding of diabetes; 5. likelihood to recommend present treatment; and 6. satisfaction to continue present treatment. Each item is rated on a 7-point Likert scale from -3 (much less satisfied) to +3 (much more satisfied). Scores from these 6 items are summed to produce the Total Score of Treatment Satisfaction, ranging from -18 (much less satisfied) to +18 (much more satisfied). The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.

    Time frame: Week 40

07

Results

Posted Oct 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Started240241241240
Received at least one dose of study drug240241241240
Completed230225225231
Not completed1016169
Withdrew: Withdrawal by subject4866
Withdrew: Lost to follow-up3532
Withdrew: Adverse event3360
Withdrew: Death0001
Withdrew: Non-compliance with study drug0010

Outcome measures

PrimaryChange From Baseline in HbA1c [Noninferiority Analysis]

* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE were calculated using a mixed-model repeated measures (MMRM) analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<= \[less than or equal to\] 8.0% ,\> \[greater than\] 8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c [Noninferiority Analysis]
percentage of HbA1cOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in HbA1c [Noninferiority Analysis]-1.32 ± 0.074-1.74 ± 0.062-1.73 ± 0.079-0.76 ± 0.076
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · Least square (ls) mean difference (net): -0.56 · 95% CI -0.76 to -0.35
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · Ls mean difference (net): -0.98 · 95% CI -1.17 to -0.79
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · Ls mean difference (net): -0.96 · 95% CI -1.18 to -0.75
SecondaryChange From Baseline in HbA1c [Superiority Analysis]

* HbA1c is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over a prolonged period of time. * Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c [Superiority Analysis]
percentage of HbA1cOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in HbA1c [Superiority Analysis]-1.32 ± 0.074-1.74 ± 0.062-1.73 ± 0.079-0.76 ± 0.076
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.56 · 95% CI -0.76 to -0.35
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.98 · 95% CI -1.17 to -0.79
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.96 · 95% CI -1.18 to -0.75
SecondaryPercentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analyzed using a logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)
percentage of participantsOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)63.2580.0977.9437.03
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 26.21 · 95% CI 17.82 to 34.60
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 43.05 · 95% CI 34.86 to 51.24
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 40.91 · 95% CI 32.43 to 49.38
SecondaryPercentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)

Percentage of participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)
percentage of participantsOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)54.6266.6968.6221.59
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 33.03 · 95% CI 25.01 to 41.05
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 45.10 · 95% CI 36.96 to 53.25
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 47.04 · 95% CI 38.60 to 55.47
SecondaryPercent Change From Baseline in Body Weight

Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight
percent changeOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percent Change From Baseline in Body Weight-3.5 ± 0.38-6.3 ± 0.40-7.3 ± 0.49-3.0 ± 0.27
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.255 · Ls mean difference (net): -0.5 · 95% CI -1.4 to 0.4
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.4 · 95% CI -4.3 to -2.4
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -4.4 · 95% CI -5.5 to -3.3
SecondaryChange From Baseline in Body Weight

Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in Body Weight-3.2 ± 0.33-5.8 ± 0.37-6.8 ± 0.46-2.7 ± 0.25
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.272 · Ls mean difference (net): -0.5 · 95% CI -1.3 to 0.4
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.1 · 95% CI -4.0 to -2.2
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -4.0 · 95% CI -5.1 to -3.0
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol

Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol
percent changeOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol-2.80 ± 1.634-8.17 ± 1.597-4.99 ± 1.7740.06 ± 1.766
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.234 · Geometric ls mean difference (net): -2.86 · 95% CI -7.39 to 1.90
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -8.23 · 95% CI -12.58 to -3.66
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.044 · Geometric ls mean difference (net): -5.05 · 95% CI -9.71 to -0.14
SecondaryPercent Change From Baseline in Triglycerides

Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Triglycerides
percent changeOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percent Change From Baseline in Triglycerides-9.87 ± 2.499-12.74 ± 2.704-14.76 ± 2.447-4.00 ± 2.594
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.103 · Geometric ls mean difference (net): -6.12 · 95% CI -12.98 to 1.29
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.020 · Geometric ls mean difference (net): -9.11 · 95% CI -16.15 to -1.47
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.003 · Geometric ls mean difference (net): -11.21 · 95% CI -17.81 to -4.07
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in Systolic Blood Pressure (SBP)-2.8 ± 0.65-5.1 ± 0.69-5.8 ± 0.68-3.8 ± 0.59
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.225 · Ls mean difference (net): 1.1 · 95% CI -0.7 to 2.8
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.157 · Ls mean difference (net): -1.3 · 95% CI -3.1 to 0.5
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.028 · Ls mean difference (net): -2.0 · 95% CI -3.8 to -0.2
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in Fasting Serum Glucose (FSG)-32.3 ± 2.55-43.1 ± 2.39-43.9 ± 2.44-22.5 ± 2.91
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.011 · Ls mean difference (net): -9.9 · 95% CI -17.5 to -2.3
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -20.7 · 95% CI -28.1 to -13.3
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -21.4 · 95% CI -28.9 to -14.0
SecondaryPercentage of Participants With ≥ 5% Body Weight Reduction

Percentage of participants with greater than or equal to (≥) 5% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 5% Body Weight Reduction
percentage of participantsOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percentage of Participants With ≥ 5% Body Weight Reduction38.5755.8961.2627.91
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = 0.017 · Risk difference (rd): 10.66 · 95% CI 1.92 to 19.40
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 27.98 · 95% CI 19.14 to 36.81
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 33.34 · 95% CI 24.56 to 42.12
SecondaryPercentage of Participants With ≥ 10% Body Weight Reduction

Percentage of participants with ≥ 10% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 10% Body Weight Reduction
percentage of participantsOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percentage of Participants With ≥ 10% Body Weight Reduction14.1529.7433.605.68
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = 0.003 · Risk difference (rd): 8.47 · 95% CI 2.87 to 14.08
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 24.06 · 95% CI 17.23 to 30.89
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 27.92 · 95% CI 20.93 to 34.91
SecondaryPercentage of Participants With ≥ 15% Body Weight Reduction

Percentage of participants with ≥ 15% body weight reduction was analyzed by logistic regression model with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by baseline HbA1c levels (\<=8.0% and \>8.0%). Missing Week 40 data were imputed using a multiple imputation method.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 15% Body Weight Reduction
percentage of participantsOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percentage of Participants With ≥ 15% Body Weight Reduction3.188.9317.461.06
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = 0.152 · Risk difference (rd): 2.12 · 95% CI -0.78 to 5.02
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 7.87 · 95% CI 3.46 to 12.29
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Regression, Logistic · p = <.001 · Risk difference (rd): 16.40 · 95% CI 11.01 to 21.79
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)

Values represented under "Least Squares (LS) Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures, with country, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Change From Baseline in Diastolic Blood Pressure (DBP)0.3 ± 0.49-1.4 ± 0.49-1.3 ± 0.47-1.7 ± 0.39
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.001 · Ls mean difference (net): 2.0 · 95% CI 0.8 to 3.3
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.648 · Ls mean difference (net): 0.3 · 95% CI -0.9 to 1.5
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.495 · Ls mean difference (net): 0.4 · 95% CI -0.8 to 1.6
SecondaryPercent Change From Baseline in Total Cholesterol

Values represented under "Geometric LS Mean" are MBE of the unconditional average treatment effect. MBE were calculated using MMRM analysis for post-baseline measures: log (actual measurement/baseline) = country, log (baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of HbA1c level (\<=8.0%, \>8.0%). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Total Cholesterol
percent changeOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Percent Change From Baseline in Total Cholesterol-1.13 ± 1.273-5.06 ± 1.177-3.13 ± 1.3071.00 ± 1.359
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.253 · Geometric ls mean difference (net): -2.11 · 95% CI -5.62 to 1.54
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -6.00 · 95% CI -9.31 to -2.57
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.029 · Geometric ls mean difference (net): -4.09 · 95% CI -7.60 to -0.44
SecondaryChange From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores
T-scoreOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Physical Component Score2.99 ± 0.4733.06 ± 0.4342.62 ± 0.4432.26 ± 0.442
Mental Component Score0.71 ± 0.5610.44 ± 0.4581.10 ± 0.5550.57 ± 0.478
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.234 · Ls mean difference (net): 0.73 · 95% CI -0.47 to 1.94
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.166 · Ls mean difference (net): 0.80 · 95% CI -0.34 to 1.95
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.539 · Ls mean difference (net): 0.36 · 95% CI -0.80 to 1.52
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.848 · Ls mean difference (net): 0.14 · 95% CI -1.26 to 1.53
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.838 · Ls mean difference (net): -0.13 · 95% CI -1.39 to 1.12
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.451 · Ls mean difference (net): 0.53 · 95% CI -0.85 to 1.91
SecondaryDiabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction

The DTSQc assesses relative change in participant satisfaction with diabetes treatment compared to previous treatment. The questionnaire consists of 8 items, of which 6 items were used to calculate the Total Score of Treatment Satisfaction, covering the following:1. satisfaction with current treatment; 2. convenience of treatment; 3. flexibility; 4. satisfaction with understanding of diabetes; 5. likelihood to recommend present treatment; and 6. satisfaction to continue present treatment. Each item is rated on a 7-point Likert scale from -3 (much less satisfied) to +3 (much more satisfied). Scores from these 6 items are summed to produce the Total Score of Treatment Satisfaction, ranging from -18 (much less satisfied) to +18 (much more satisfied). The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.

Time frame:
Week 40
Reported as:
Least squares mean · score on a scale
Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction
score on a scaleOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc): Total Score of Treatment Satisfaction15.28 ± 0.44415.04 ± 0.51615.33 ± 0.61515.22 ± 0.357
Statistical analysis
  • Orforglipron 3 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.915 · Ls mean difference (net): 0.06 · 95% CI -1.08 to 1.20
  • Orforglipron 12 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.784 · Ls mean difference (net): -0.17 · 95% CI -1.42 to 1.07
  • Orforglipron 36 mg vs Dapagliflozin 10 mg · ANCOVA · p = 0.878 · Ls mean difference (net): 0.11 · 95% CI -1.36 to 1.59

Adverse events

Collected over Baseline Up to Week 42. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Orforglipron 3 mg0/240 (0%)8/240 (3.3%)174/240 (72.5%)
Orforglipron 12 mg0/241 (0%)14/241 (5.8%)180/241 (74.7%)
Orforglipron 36 mg0/241 (0%)10/241 (4.1%)180/241 (74.7%)
Dapagliflozin 10 mg1/240 (0.4%)11/240 (4.6%)154/240 (64.2%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
Atrial fibrillationCardiac disorders0/2401/2410/2412/240
Angina unstableCardiac disorders0/2400/2410/2411/240
Arteriosclerosis coronary arteryCardiac disorders0/2400/2410/2411/240
Cardiac failure chronicCardiac disorders0/2401/2410/2411/240
Coronary artery diseaseCardiac disorders0/2401/2410/2411/240
TachyarrhythmiaCardiac disorders0/2400/2410/2411/240
VertigoEar and labyrinth disorders0/2400/2410/2411/240
Obstructive pancreatitisGastrointestinal disorders1/2400/2410/2410/240
Septic shockInfections and infestations0/2400/2410/2411/240
Urinary tract infectionInfections and infestations1/2400/2410/2410/240
Most frequent other events
Showing 10 of 483
Most frequent other events
EventOrforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mg
NauseaGastrointestinal disorders47/24043/24154/2414/240
DiarrhoeaGastrointestinal disorders44/24040/24148/24112/240
Diabetic retinopathyEye disorders29/24030/24127/24137/240
VomitingGastrointestinal disorders19/24020/24129/2414/240
ConstipationGastrointestinal disorders19/24020/24125/2412/240
DyspepsiaGastrointestinal disorders15/24012/24125/2412/240
Abdominal distensionGastrointestinal disorders12/24013/24120/2413/240
Decreased appetiteMetabolism and nutrition disorders12/2408/24120/2410/240
NasopharyngitisInfections and infestations17/24014/24116/24110/240
HyperglycaemiaMetabolism and nutrition disorders14/2406/2413/24115/240

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
Mean55.1 ± 11.855.9 ± 11.656.6 ± 11.556.6 ± 11.156.1 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
Female117121123113474
Male123120118127488
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
Hispanic or Latino114114116114458
Not Hispanic or Latino124125122124495
Unknown or Not Reported22329
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
American Indian or Alaska Native67625361243
Asian43424442171
Native Hawaiian or Other Pacific Islander00000
Black or African American662620
White119125131125500
More than one race5511627
Unknown or Not Reported01001
Region of Enrollment
Region of Enrollment(Participants)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
China25262526102
Germany30292929117
Mexico99100100100399
Poland36363635143
Taiwan1515151560
United States35353635141
HemoglobinA1c (HbA1c)
HemoglobinA1c (HbA1c)(Percentage of HbA1c)Orforglipron 3 mgOrforglipron 12 mgOrforglipron 36 mgDapagliflozin 10 mgTotal
Mean8.17 ± 1.088.11 ± 1.058.18 ± 1.088.09 ± 0.988.14 ± 1.04
08

Study locations

74 sites
  • Alliance Research Institute - Canoga Park
    Canoga Park, California 91304, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • Wolverine Clinical Trials
    Santa Ana, California 92706, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Institute of Endocrinology Diabetes, Health & Hormone
    Stockbridge, Georgia 30281, United States
  • Elite Clinical Trials
    Rexburg, Idaho 83440, United States
  • Accellacare - DuPage
    Lombard, Illinois 60148, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • St. Vincent Healthcare
    Billings, Montana 59101, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Accellacare - Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • Essential Medical Research
    Tulsa, Oklahoma 74137, United States
  • Accellacare - Mt Pleasant
    Mt. Pleasant, South Carolina 29464, United States
  • Accellacare, US Inc., d/b/a Accellacare of Knoxville
    Jefferson City, Tennessee 37760, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230011, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan 473007, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • CRS Clinical Research Services Mannheim
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz
    Lingen, Lower Saxony 49808, Germany
  • Diabetes- und Stoffwechselpraxis Bochum
    Bochum, North Rhine-Westphalia 44869, Germany
  • Zentrum fur klinische Forschung - Köln
    Cologne, North Rhine-Westphalia 51069, Germany
  • InnoDiab Forschung Gmbh
    Essen, North Rhine-Westphalia 45136, Germany
  • Medizentrum Essen Borbeck
    Essen, North Rhine-Westphalia 45355, Germany
  • Institut für Diabetesforschung GmbH Münster
    Münster, North Rhine-Westphalia 48145, Germany
  • Praxis Dr. Veronika Wenzl-Bauer
    Rehlingen, Saarland 66780, Germany
  • Zentrum für klinische Studien
    Saint Ingbert, Saarland 66386, Germany
  • RED-Institut GmbH
    Oldenburg in Holstein, Schleswig-Holstein 23758, Germany
  • Diabetes Zentrum Wilhelmsburg
    Hamburg, 21109, Germany
  • Grupo Ollin Care
    Pachuca, Hidalgo 42000, Mexico
  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad
    Guadalajara, Jalisco 44600, Mexico
  • Cryptex Investigación Clínica S.A. de C.V.
    Cuauhtémoc, Ciudad de México, Mexico City 06100, Mexico
  • ProcliniQ Investigación Clínica SA de CV
    Mexico City, Mexico City 14050, Mexico
  • Instituto de Diabetes, Obesidad y Nutricion
    Cuernavaca, Morelos 62250, Mexico
  • Cardiolink Clin Trials
    Monterrey, Nuevo León 64060, Mexico
  • Clínica García Flores SC
    Monterrey, Nuevo León 64610, Mexico
  • Servicios Integrales Nova de Monterrey S.A. de C.V.
    San Nicolás de los Garza, Nuevo León 66450, Mexico
  • Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
    Culiacán, Sinaloa 80230, Mexico
  • Consultorio de Medicina Especilizada del Sector Privado
    Xalapa, Veracruz 91193, Mexico
  • Hospital Angeles Xalapa
    Xalapa, Veracruz 91193, Mexico
  • Fundación Cardiovascular de Aguascalientes A.C.
    Aguascalientes, 20230, Mexico
  • Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia
    Durango, 34000, Mexico
  • NZOZ Centrum Medyczne KERmed
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-231, Poland
  • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET
    Krakow, Lesser Poland Voivodeship 31-261, Poland
  • Centrum Badań Klinicznych Piotr Napora lekarze sp.p.
    Wroclaw, Lower Silesian Voivodeship 50-162, Poland
  • Clinical Best Solutions
    Lublin, Lublin Voivodeship 20-011, Poland
  • CenterMed Lublin NZOZ
    Lublin, Lublin Voivodeship 20-044, Poland
  • Ekamed
    Lublin, Lublin Voivodeship 20-718, Poland
  • Centrum Medyczne "Diabetika"
    Radom, Masovian Voivodeship 26-600, Poland
  • Zdrowie Osteo-Medic
    Bialystok, Podlaskie Voivodeship 15-351, Poland
  • Specderm Poznanska
    Bialystok, Podlaskie Voivodeship 15-375, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 SUM
    Zabrze, Silesian Voivodeship 41-800, Poland
  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
    Lodz, Łódź Voivodeship 90-338, Poland
  • Chang Gung Memorial Hospital at Kaohsiung
    Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 81362, Taiwan
  • Fu Jen Catholic University Hospital
    New Taipei City, 24352, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet. 2026 Jul 11;408(10550):125-140. doi: 10.1016/S0140-6736(26)00800-7. Epub 2026 Jun 8. PubMed 42259339 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2025, 20 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 5, 2024
StartActual
Jan 10, 2024
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Interventions
Arm changed Orforglipron Dose 3→Orforglipron 3 mg; Dapagliflozin→Dapagliflozin 10 mg. Arms added: Orforglipron 12 mg·Orforglipron 36 mg; arms removed: Orforglipron Dose 1·Orforglipron Dose 2
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Hemoglobin A1c: (HbA1c)HbA1c [Noninferiority Analysis]Time frame: Baseline, Week 40
Oct 16, 2026
Documents
Secondary outcomes
16 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in HbA1c [Superiority Analysis]Time frame: Baseline, Week 40
  • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of < 7.0% (53 millimole/mole(mmol/molMol))Time frame: Week 40
  • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of ≤6.5% (48 mmol/molMol)Time frame: Week 40
  • EditedPercentagePercent Change fromFrom Baseline in Body WeightTime frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Body WeightTime frame: Baseline, Week 40
  • EditedPercentagePercent Change fromFrom Baseline in Non-High-Density Lipoprotein (nonNon-HDL)- CholesterolTime frame: Baseline, Week 40
  • EditedPercentagePercent Change fromFrom Baseline in TriglyceridesTime frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Systolic Blood Pressure (SBP)Time frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 40
  • EditedPercentage of Participants Who AchievedWith ≥ 5% Body Weight Loss of ≥5% from BaselineReductionTime frame: Baseline to Week 40 → Week 40
  • EditedPercentage of Participants Who AchievedWith ≥ 10% Body Weight Loss of ≥10% from baselineReductionTime frame: Baseline to Week 40 → Week 40
  • EditedPercentage of Participants Who AchievedWith ≥ 15% Body Weight Loss of ≥15% from baselineReductionTime frame: Baseline to Week 40 → Week 40
  • EditedChange fromFrom Baseline in Diastolic Blood Pressure (DBP)Time frame: Baseline, Week 40
  • EditedPercentagePercent Change fromFrom Baseline in Total CholesterolTime frame: Baseline, Week 40
  • EditedChange fromFrom Baseline in Short Form 36-36 Health Survey Version 2 (SF-36-v236v2) Acute Form Domain Summary(Physical-Component and Mental-Component) ScoresTime frame: Baseline, Week 40
  • EditedChange from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc) Scores: Total Score of Treatment SatisfactionTime frame: Baseline, Week 40 → Week 40
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Hemoglobin A1c: (HbA1c)HbA1c [Noninferiority Analysis]Time frame: Baseline, Week 40
    Secondary outcomes 16 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in HbA1c [Superiority Analysis]Time frame: Baseline, Week 40
    • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of < 7.0% (53 millimole/mole(mmol/molMol))Time frame: Week 40
    • EditedPercentage of Participants Who AchievedWith an HbA1c Target Value of ≤6.5% (48 mmol/molMol)Time frame: Week 40
    • EditedPercentagePercent Change fromFrom Baseline in Body WeightTime frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Body WeightTime frame: Baseline, Week 40
    • EditedPercentagePercent Change fromFrom Baseline in Non-High-Density Lipoprotein (nonNon-HDL)- CholesterolTime frame: Baseline, Week 40
    • EditedPercentagePercent Change fromFrom Baseline in TriglyceridesTime frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Systolic Blood Pressure (SBP)Time frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Fasting Serum Glucose (FSG)Time frame: Baseline, Week 40
    • EditedPercentage of Participants Who AchievedWith ≥ 5% Body Weight Loss of ≥5% from BaselineReductionTime frame: Baseline to Week 40 → Week 40
    • EditedPercentage of Participants Who AchievedWith ≥ 10% Body Weight Loss of ≥10% from baselineReductionTime frame: Baseline to Week 40 → Week 40
    • EditedPercentage of Participants Who AchievedWith ≥ 15% Body Weight Loss of ≥15% from baselineReductionTime frame: Baseline to Week 40 → Week 40
    • EditedChange fromFrom Baseline in Diastolic Blood Pressure (DBP)Time frame: Baseline, Week 40
    • EditedPercentagePercent Change fromFrom Baseline in Total CholesterolTime frame: Baseline, Week 40
    • EditedChange fromFrom Baseline in Short Form 36-36 Health Survey Version 2 (SF-36-v236v2) Acute Form Domain Summary(Physical-Component and Mental-Component) ScoresTime frame: Baseline, Week 40
    • EditedChange from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change Version (DTSQc) Scores: Total Score of Treatment SatisfactionTime frame: Baseline, Week 40 → Week 40
    Interventions Arm changed Orforglipron Dose 3→Orforglipron 3 mg; Dapagliflozin→Dapagliflozin 10 mg. Arms added: Orforglipron 12 mg·Orforglipron 36 mg; arms removed: Orforglipron Dose 1·Orforglipron Dose 2
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06192108
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 10, 2024
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion